N/A N=38 Measurements of Angulation of the C-spine
Cervical Spine
Primary: Measurements of Angulation of the Neck (C-spine) on MRI Scans — 10.6; 21.6; 5.5; 4.1 degrees — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=79 C7-T1 Epidural Steroid Injections Versus Targeted Injection for Treatment of Cervical Radicular Pain
Radicular; Neuropathic, Cervical · Neck Pain
Primary: Percentage of Participants With ≥50% Pain Reduction on the Numeric Rating Score (NRS) for Pain — 60; 72 percentage of participants — p=0.23
Phase 2 N=10 Tailored Computerized Mobilization of the Cervical Spine Utilizing the Occiflex Device for the Treatment of Chronic Neck Pain
Neck Pain
Primary: Occiflex Device Safety — 26 Number of adverse effects
Phase 3 N=12,167 Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)
Cervical Cancer · Genital Warts
Primary: Incidence of the Composite Endpoint of Human Papillomavirus (HPV) 16/18-related Cervical Intraepithelial Neoplasia (CIN) 2 or Worse in the Base Study — 0.0; 0.4…
N/A N=30 Cervical Activation During Elastic and Manual Resistance
Cervical Pain
Primary: Percent of Peak Activation (%PA) — 51.72; 61.20; 88.1; 80.80 Percentage of Peak Activation (%PA)
N/A N=29 Ultrasound-guided Intermediate Cervical Plexus Block
Internal Carotid Artery Stenosis
Primary: Local Anesthetic Supplementation (Frequency) — 11; 7 participants — p=0.236
Phase 3 N=5,759 Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)
Cervical Cancer · Genital Warts
Primary: Incidence of HPV 6/11/16/18-related Cervical Intraepithelial Neoplasia (CIN)(Any Grade), Adenocarcinoma In Situ (AIS) or Cervical Cancer — 0; 1.2 incidence rate per 100…
Phase 2 N=133 Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)
Cervical Intraepithelial Neoplasia · Cervical Dysplasia
Primary: Incidence of Objective Response — 32; 36; 30; 0 Participants — p=0.043
Phase 2 N=74 Transforaminal Versus Lateralized Interlaminar Cervical Epidurals
Cervicogenic Upper Extremity Radiculopathy
Primary: Change in Pain Numerical Rating Scale (Averaged Over Past 24 Hours) — -3.38; -2.30 score on a scale — p=0.057
N/A N=45 Coherence Imaging of the Cervical Epithelium With Scanning a/LCI
Cervical Dysplasia
Primary: Sensitivity of Scanning a/LCI Probe to Detect Cervical Dysplasia as Measured by Percentage of Correctly Identified Positive Biopsies — 90.3; 100.0 percentage of correct…
N/A N=55 Coherence Imaging of the Cervical Epithelium
Cervical Epithelia
Primary: Number of Patients With Interferometric Data Acquired From Cervical Epithelium — 3; 41 patients
Phase 4 N=65 Surgery Prevention by Transforaminal Injection of Epidural Steroids for Cervical Radicular Pain
Pain, Radiating
Primary: Avoidance of Neck Surgery — 24; 20; 3; 6 Participants
Phase 2 N=130 Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
Cervical Carcinoma · Cervical Intraepithelial Neoplasia Grade 2/3 · Stage 0 Cervical Cancer
Primary: Histologic Regression — 40; 34.1 percentage of participants
N/A N=231 Outcome Study of Patients Treated With Translational Cervical Plate Used to Treat Degenerative Disc Disease
Degenerative Disc Disease
Primary: Radiographic Fusion — 66; 46; 37; 75 percentage of subjects
N/A N=710 INFUSE® Bone Graft/ PEEK Interbody Spacer/ Anterior Cervical Plate Pivotal Clinical Trial
Degenerative Disc Disease
Primary: Rate of Overall Success — 80.9; 59.9 percentage of participants — p=<0.001
Phase 3 N=545 Study of Safety & Effectiveness of PRESTIGE® LP Cervical Disc vs. Anterior Cervical Fusion in Cervical DDD
Cervical Degenerative Disc Disease
Primary: Rate of Overall Success — 70.4; 63.2 percentage of participants — p=0.995
N/A N=89 SECURE®-C Cervical Artificial Disc Clinical Study/ SECURE-C Cervical Artificial Disc Postmarket Approval Study
Symptomatic Cervical Disc Disease
Primary: Individual Patient Overall Success — 127; 81; 67 participants
N/A N=575 LDR Spine USA Mobi-C(R) Cervical Disc Prosthesis IDE
Degenerative Disc Disease
Primary: Composite Definition of Study Success — 65.3; 73.7; 37.4; 69.7 percentage of subjects analyzed — p=0.0021
Phase 3 N=465 PREGNANT Short Cervix Trial
Preterm Delivery · Short Cervix · Short Uterine Cervical Length
Primary: Number of Participants With Birth <=32 6/7 Weeks Gestation. — 36; 21 participants — p=0.020
N/A N=397 Study of the Safety and Effectiveness of the Artificial Cervical Disc - Low Profile Device at Two Adjacent Levels
Cervical Degenerative Disc Disease · Radiculopathy · Myelopathy
Primary: Rate of Overall Success — 81.4; 69.4 percentage of participants — p=1.000
N/A N=20 Cervix Monitor for Elasticity and Length Measurements
Preterm Birth
Primary: Cervix Elasticity — 54; 19.7 kPa
Phase 3 N=416 PCM Cervical Disc System
Radiculopathy · Myelopathy
Primary: Individual Patient Overall Success — 142; 98 participants
N/A N=104 Interbody Fusion Devices in the Treatment of Cervicobrachial Syndrome
Radiating Pain · Myelopathy · Cervicobrachial Syndrome
Primary: Neck Disability Index — 17.9; 16.7 units on a scale from 0 to 100 — p=0.641
N/A N=30 Clavicle Splint for Pain Reduction After Posterior Cervicothoracic Surgery
Posterior Cervical Surgery · Posterior Cervical Fusion · Posterior Cervical Laminectomy
Primary: Average Neck Pain Level — 1; 1 units on a scale (VAS pain scale)
N/A N=50 Clinical Investigation To Evaluate Cerviron Ovules® in Symptomatic Vaginitis
Vaginitis and Vulvovaginitis
Primary: Number of Participants With the Same Gynaecological Conditions at the End of Treatment Visit — 13 Participants
Phase 3 N=225 A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years
Infections, Papillomavirus
Primary: Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies — 125; 2; 122; 3 Participants
N/A N=267 Investigation of the Simplify® Cervical Artificial Disc
Cervical Degenerative Disc Disease
Primary: Number of Participants With Composite Clinical Success (CCS) of Simplify Disc — 68; 132 Participants — p=<.001
N/A N=19 Driving After Cervical Spine Surgery
Cervical Disc Disease
Primary: Change in Number of Total Collisions (TC) — 2 collisions/crashes
Phase 3 N=364 Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer
Cervical Cancer
Primary: Overall Survival — 21.9; 19.5 months — p=0.125
Phase 2 N=18 CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer
Cervical Cancer · Endometrial Cancer · Ovarian Cancer
Primary: Number of Patients With Measurable Concentration of Gemcitabine in Uterine Vein (dFdC) — 5 Participants